Black women comprised only 7% and Hispanic women only 6% of the endometrial cancer clinical trials conducted between 1988 and 2019 that specified the race and ethnicity of participants. During that time period, less than 10% of the trials reported race and 5% reported ethnicity of the women.
“The first step in addressing cancer care disparities involves transparency in reporting enrollment of racial and ethnic minorities in clinical trials among women with gynecologic cancers,” the investigators wrote. “Reporting of race and ethnicity should be required for all clinical trials.”
- See “Race, Ethnicity ‘Notably Underreported’ in Publicly Accessible Databases of Gynecologic Cancer Trials” by Nicholas Wrigley on the Cancer Network website (November 29, 2022)
- See the abstract of the scientific paper “Diversity and transparency in gynecologic oncology clinical trials” by Mary Katherine Montes de Oca et al.
